|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDT1 |
Gene summary for CDT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDT1 | Gene ID | 81620 |
| Gene name | chromatin licensing and DNA replication factor 1 | |
| Gene Alias | DUP | |
| Cytomap | 16q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q9H211 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81620 | CDT1 | P1T-E | Human | Esophagus | ESCC | 9.99e-03 | 3.60e-01 | 0.0875 |
| 81620 | CDT1 | P2T-E | Human | Esophagus | ESCC | 3.24e-19 | 6.20e-01 | 0.1177 |
| 81620 | CDT1 | P4T-E | Human | Esophagus | ESCC | 1.83e-16 | 5.22e-01 | 0.1323 |
| 81620 | CDT1 | P5T-E | Human | Esophagus | ESCC | 1.73e-35 | 7.31e-01 | 0.1327 |
| 81620 | CDT1 | P8T-E | Human | Esophagus | ESCC | 1.21e-20 | 5.12e-01 | 0.0889 |
| 81620 | CDT1 | P10T-E | Human | Esophagus | ESCC | 2.57e-02 | 9.82e-02 | 0.116 |
| 81620 | CDT1 | P12T-E | Human | Esophagus | ESCC | 7.00e-03 | 1.58e-01 | 0.1122 |
| 81620 | CDT1 | P15T-E | Human | Esophagus | ESCC | 7.75e-12 | 4.68e-01 | 0.1149 |
| 81620 | CDT1 | P16T-E | Human | Esophagus | ESCC | 3.39e-05 | 2.49e-01 | 0.1153 |
| 81620 | CDT1 | P17T-E | Human | Esophagus | ESCC | 1.39e-07 | 6.93e-01 | 0.1278 |
| 81620 | CDT1 | P21T-E | Human | Esophagus | ESCC | 5.55e-07 | 2.02e-01 | 0.1617 |
| 81620 | CDT1 | P22T-E | Human | Esophagus | ESCC | 2.80e-07 | 2.81e-01 | 0.1236 |
| 81620 | CDT1 | P23T-E | Human | Esophagus | ESCC | 1.00e-07 | 4.10e-01 | 0.108 |
| 81620 | CDT1 | P24T-E | Human | Esophagus | ESCC | 4.01e-18 | 5.36e-01 | 0.1287 |
| 81620 | CDT1 | P26T-E | Human | Esophagus | ESCC | 1.60e-10 | 4.31e-01 | 0.1276 |
| 81620 | CDT1 | P27T-E | Human | Esophagus | ESCC | 3.93e-06 | 1.94e-01 | 0.1055 |
| 81620 | CDT1 | P28T-E | Human | Esophagus | ESCC | 3.86e-18 | 4.65e-01 | 0.1149 |
| 81620 | CDT1 | P31T-E | Human | Esophagus | ESCC | 1.41e-30 | 8.94e-01 | 0.1251 |
| 81620 | CDT1 | P32T-E | Human | Esophagus | ESCC | 1.94e-21 | 4.73e-01 | 0.1666 |
| 81620 | CDT1 | P37T-E | Human | Esophagus | ESCC | 2.77e-07 | 3.34e-01 | 0.1371 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051306 | Liver | HCC | mitotic sister chromatid separation | 44/7958 | 67/18723 | 1.08e-04 | 9.22e-04 | 44 |
| GO:0030071 | Liver | HCC | regulation of mitotic metaphase/anaphase transition | 40/7958 | 60/18723 | 1.34e-04 | 1.10e-03 | 40 |
| GO:0033045 | Liver | HCC | regulation of sister chromatid segregation | 46/7958 | 72/18723 | 2.02e-04 | 1.56e-03 | 46 |
| GO:0044784 | Liver | HCC | metaphase/anaphase transition of cell cycle | 42/7958 | 65/18723 | 2.63e-04 | 1.94e-03 | 42 |
| GO:0051310 | Liver | HCC | metaphase plate congression | 42/7958 | 65/18723 | 2.63e-04 | 1.94e-03 | 42 |
| GO:0031570 | Liver | HCC | DNA integrity checkpoint | 71/7958 | 123/18723 | 4.64e-04 | 3.08e-03 | 71 |
| GO:1901988 | Liver | HCC | negative regulation of cell cycle phase transition | 132/7958 | 249/18723 | 4.97e-04 | 3.25e-03 | 132 |
| GO:0033047 | Liver | HCC | regulation of mitotic sister chromatid segregation | 31/7958 | 46/18723 | 5.67e-04 | 3.61e-03 | 31 |
| GO:00345021 | Liver | HCC | protein localization to chromosome | 55/7958 | 92/18723 | 6.12e-04 | 3.82e-03 | 55 |
| GO:0045839 | Liver | HCC | negative regulation of mitotic nuclear division | 32/7958 | 48/18723 | 6.21e-04 | 3.86e-03 | 32 |
| GO:1902099 | Liver | HCC | regulation of metaphase/anaphase transition of cell cycle | 40/7958 | 63/18723 | 6.22e-04 | 3.86e-03 | 40 |
| GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
| GO:00900683 | Liver | HCC | positive regulation of cell cycle process | 125/7958 | 236/18723 | 7.21e-04 | 4.40e-03 | 125 |
| GO:0010948 | Liver | HCC | negative regulation of cell cycle process | 152/7958 | 294/18723 | 8.50e-04 | 5.08e-03 | 152 |
| GO:004593111 | Liver | HCC | positive regulation of mitotic cell cycle | 69/7958 | 121/18723 | 8.79e-04 | 5.20e-03 | 69 |
| GO:1901991 | Liver | HCC | negative regulation of mitotic cell cycle phase transition | 97/7958 | 179/18723 | 1.03e-03 | 5.91e-03 | 97 |
| GO:0007094 | Liver | HCC | mitotic spindle assembly checkpoint | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
| GO:0071173 | Liver | HCC | spindle assembly checkpoint | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
| GO:0071174 | Liver | HCC | mitotic spindle checkpoint | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
| GO:0050000 | Liver | HCC | chromosome localization | 49/7958 | 82/18723 | 1.20e-03 | 6.68e-03 | 49 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDT1 | SNV | Missense_Mutation | c.545C>A | p.Pro182Gln | p.P182Q | Q9H211 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDT1 | SNV | Missense_Mutation | novel | c.1018G>T | p.Val340Leu | p.V340L | Q9H211 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.468G>T | p.Glu156Asp | p.E156D | Q9H211 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CDT1 | SNV | Missense_Mutation | novel | c.466N>A | p.Glu156Lys | p.E156K | Q9H211 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.466G>A | p.Glu156Lys | p.E156K | Q9H211 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CDT1 | SNV | Missense_Mutation | novel | c.641C>A | p.Pro214His | p.P214H | Q9H211 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CDT1 | SNV | Missense_Mutation | c.1621C>T | p.Arg541Cys | p.R541C | Q9H211 | protein_coding | deleterious(0.02) | possibly_damaging(0.676) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| CDT1 | SNV | Missense_Mutation | novel | c.310N>A | p.Ala104Thr | p.A104T | Q9H211 | protein_coding | tolerated(0.32) | benign(0.039) | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.1118C>T | p.Pro373Leu | p.P373L | Q9H211 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDT1 | SNV | Missense_Mutation | novel | c.1065G>T | p.Glu355Asp | p.E355D | Q9H211 | protein_coding | tolerated(0.47) | benign(0.07) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |